CLEARWATER, Florida, October 30, 2013 /PRNewswire/ --
Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, presented a poster at the 12th Annual Meeting of the North East ALS (NEALS) Consortium which took place 3rd-4th October 2013, at the Sandpearl Resort, Clearwater Beach, FL, USA. The poster was entitled "1H-MRS & FDG-PET studies in the SOD1 G93A - the use of stabilized peptides as a rationale for future treatment in ALS" and was co-authored by scientists and researchers from Daval and Charles River Discovery Research Services, Finland.
The North East ALS Consortium is an alliance of medical institutions that are equipped to perform clinical trials in Amyotrophic Lateral Sclerosis (ALS) and motor neuron diseases. The Annual NEALS Meeting serves as an opportunity for NEALS researchers to liaise with leading ALS and motor neuron disease scientists, government sponsors, academic partners and pharmaceutical companies in order to discuss potential treatments, to review current research activities and to share scientific updates.
The objectives of the studies were to determine whether targeting of the hypothalmo-pituitary-adrenal axis at a specific site using AIMSPRO®, the novel multi-protein-peptide conjugate complex, currently in clinical development, could elicit multiple measurable efficacy traits in the G93A SOD1 murine model. The SOD-1 model is the most studied ALS mouse model and the results showed clinical efficacy, associated changes in brainstem 1H-MRS metabolites and appeared to target glutamate/glutamine availability and in a separate study rescued the G93A SOD1 brain from hypometabolism.
Professor Syed Haq, Daval's Chief Clinical & Scientific Officer and one of the co-authors, presented the poster in Florida and commented, "These results are extremely encouraging and supportive of other studies that have been undertaken pre-clinically as well as in double-blind, placebo-controlled clinical trials in humans. The Implications and findings has led to further work to elucidate the potential targets in ALS that may have future therapeutic implications in the treatment of patients diagnosed with ALS where glutamate exocitotoxicity and hypometabolism of the brain have been defined as potential pathogenic mechanisms in the evolution of the disease".
The poster will be available for download at the Daval International website shortly, as soon as the organisers permission has been obtained.
Notes to Editors
AIMSPRO® is a proprietary, purified, protein-multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of neurological and autoimmune diseases where regulation and stabilisation of the immune system is required. The therapeutic has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and has been granted Orphan Drug Designation for ALS by the Food & Drug Administration (FDA) in the United States.
About Daval International Limited
DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improves the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.
For further information please contact:
Edward Jensen +1-484-716-9305 or +44(0)7775-793513 firstname.lastname@example.org
Graham Ralph +44-(0)845-130-3014 email@example.com
|SOURCE Daval International|
Copyright©2012 PR Newswire.
All rights reserved